Introduction
============

Due to environmental pollution caused by industrialization, tobacco exposure, automobile exhaust pollution, host characteristics, and other factors, lung cancer cases are increasing and has become one of the most common causes of cancer-related death ([@b1-etm-0-0-4920]). In China, \~600,000 people die each year from lung cancer and lung cancer mortality ranked first among all malignant tumors ([@b2-etm-0-0-4920]). Surgery is usually characterized by severe traumatic events and long operation times. Anesthetic-induced stimulation can lead to stress and inflammatory responses, neither of which being conducive to a good prognosis ([@b3-etm-0-0-4920]). With the continuous development of minimally invasive technology, thoracoscopic lobectomy is now well-accepted for the early treatment of lung cancer by clinicians and patients, as it presents reduced surgical trauma and quicker recoveries ([@b4-etm-0-0-4920]). Therefore, anesthesia-induced inflammatory response, postoperative pain, and the incidence of adverse reactions should be reduced in order to improve patient recovery, shorten hospital stays, and reduce patient economic burdens ([@b5-etm-0-0-4920]). Nalbuphine is an opioid analgesic with a good analgesic effect ([@b6-etm-0-0-4920]). In this study, patients undergoing thoracoscopic lobectomy were treated with nalbuphine to explore its analgesic properties and effects on inflammatory cytokines, in order to identify a more suitable anesthesia program for patients undergoing early lung cancer surgery.

Materials and methods
=====================

### General patient information

Ninety-two patients with early lung cancer admitted to Xiangyang No. 1 People\'s Hospital between January 2016 and December 2016 were selected. Patients were randomly assigned to control and observation groups (n=46 each). This study was approved by the Ethics Committee of Xiangyang No. 1 People\'s Hospital. Signed written informed consents were obtained from the patients and/or guardians. Inclusion criteria were as follows: Presenting with lung cancer as diagnosed by imaging and pathological examinations, willing to receive thoracoscopic lobectomy and signed informed consent. Exclusion criteria were as follows: Presenting abnormal coagulation, presenting a history of thoracotomy, hilar and mediastinal lymph node metastasis. There were no significant differences in general characteristics between the two groups (p\>0.05; [Table I](#tI-etm-0-0-4920){ref-type="table"}).

### Methods

#### Preoperative preparation

Both groups were subjected to routine preoperative examinations, and any patients presenting surgical contraindications were excluded. Patients were asked to quit smoking 2 weeks before surgery and patients fasted for 6 h before surgery.

#### Anesthesia

Patient arterial blood pressure, pulse and electrocardiograms were monitored after entering the operating room. Prior to the induction of anesthesia, patients in the observation group received 20 mg of nalbuphine (SFDA approval no. 20130127; Yichang Renfu Pharmaceutical Co., Ltd., Yichang, China) intravenously, while control group patients received the same amount of 9% saline. A single injection of fentanyl (3 µg/kg, SFDA no. H42022076; Yichang Renfu Pharmaceutical Co., Ltd.) was performed. Intravenous injection of propofol with micropump was administered (SFDA no. H20084531; Zhejiang Jiuxu Pharmaceutical Co., Ltd., Zhejiang, China) with a target concentration of 3 µg/ml. A single injection of cisatracurium (0.02 mg/kg, SFDA no. H20060869; Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, China) was administered for the induction of anesthesia. Tracheal intubation was performed with an EEG bispectral index value below 55. Combined intravenous-inhalation anesthesia was administered by continuous infusion of remifentanil (SFDA no. H20143314; Jiangsu Nhwa Pharmaceutical Co., Ltd., Jiangsu, China) and propofol, with intermittent infusion of cisatracurium.

#### Surgical approach

Both groups of patients underwent video-assisted thoracoscopic lobectomy. Patients were in the lateral position. After conventional disinfection, an incision was made between the 7 and 8th ribs along the midaxillary line to serve as an observation hole, with another incision made between the 4 and 5th ribs along the anterior axillary line to be used as the main operating hole. A third incision was made between the 8 and 9th rib along the subscapularis line to serve as a secondary operating hole. Thoracoscopy was performed to check the thoracic cavity. Upper left lung segment, tongue segment, right upper lung anterior segment, right upper lung tip, dorsal segment, right upper lung posterior segment or other lung segments were resected according to disease conditions. Mediastinal lymph nodes were dissected and lung swelling was examined. Lung and bronchial stump leakage were also examined. Chest tube was then placed using the observation tube and the incision was sutured.

#### Inflammatory index examination

Arterial blood (5 ml) was extracted at 1, 3, 5 and 7 days after operation. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and IL-10 were measured by enzyme-linked immunosorbent assay (ELISA) using a kit from Beckman Coulter, Inc. (Brea, CA, USA). All operations were performed in strict accordance with manufacturer\'s instructions. Optical density (OD) values at 450 nm were measured by a microplate reader (Potebio, Jiangsu, China) and were used to calculate TNF-α, IL-6 and IL-10 levels.

#### Evaluation criteria

Operation time, intraoperative blood loss, and propofol and remifentanil dosages were recorded for both groups. Postoperative adverse reactions caused by anesthetics, including nausea, vomiting, dizziness and drowsiness, were also recorded.

#### Visual analogue scale (VAS). A VAS was used to assess analgesic effects

The scores ranged from 0 to 10 (0 points representing painless and 10 points indicating unbearable severe pain). Evaluation criteria were as follows: Level I: 0--2 points, painless or slight pain, excellent analgesic effect; level II: 3--5 points, tolerable pain, good analgesic effect; level III: 6--8 points, obvious pain, poor analgesic effect; and level IV: ≥8 points, intolerable pain, no analgesic effect. Analgesic efficacy = (level I + II)/no. of patients × 100%.

#### Post-operative serum inflammation index analysis

Fasting venous blood (2--5 ml) was collected from patients in the morning. Serum inflammatory factors levels, including TNF-α, IL-6 and IL-10, were measured by ELISA.

#### Statistical analysis

Data were processed using SPSS 19.0 statistical software (SPSS Inc., Chicago, IL, USA). Measurement data are expressed as mean ± standard deviation, and t-test was used for comparisons. Count data were expressed as rates and χ^2^ test was performed for comparisons. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Comparison of surgical conditions and anesthesia effects

There were no significant differences in operation time and intraoperative blood loss between the two groups. Propofol and remifentanil dosages required by the observation group were significantly lower than the control group (p\<0.05; [Table II](#tII-etm-0-0-4920){ref-type="table"}).

### Comparison of analgesic effects

The effective rate of analgesia in the observation group was significantly higher than in the control group (p\<0.05). Therefore, pain was significantly reduced in observation group (p\<0.05; [Table III](#tIII-etm-0-0-4920){ref-type="table"}).

### Comparison of adverse effects caused by anesthetics

Nausea, vomiting, dizziness and drowsiness were found in 6 patients in the observation group (incidence rate 13.04%). Those adverse effects were found in 20 patients in the control group (incidence rate 43.48%). The adverse effect incidence rate was therefore significantly lower in the observation group compared to the control group (p\<0.05; [Table IV](#tIV-etm-0-0-4920){ref-type="table"}).

### Comparison of TNF-α, IL-6 and IL-10 levels

The levels of TNF-α, IL-6 and IL-10 in the observation group were significantly lower than in the control group (p\<0.05; [Tables V](#tV-etm-0-0-4920){ref-type="table"}--[VII](#tVII-etm-0-0-4920){ref-type="table"}).

Discussion
==========

At present, the morbidity and mortality of lung cancer is showing an increasing trend, and lung cancer has become a principle killer ([@b7-etm-0-0-4920]). Early clinical manifestations of lung cancer are not obvious, and advanced lung cancer can be characterized by weight loss, fever, cough, chest tightness, shortness of breath, chest pain, bloody sputum and hemoptysis ([@b8-etm-0-0-4920]). Advanced lung cancer is usually accompanied by metastasis, leading to poor prognosis and low survival rates ([@b9-etm-0-0-4920]). Surgery is the preferred treatment for lung cancer. Compared with traditional thoracic surgery, thoracoscopic lobectomy can reduce surgical trauma, and the visual field can be amplified by video, allowing for the clearer visualization of lymph nodes and small blood vessels and reducing unnecessary damage. In addition, the separation and ligation of fine structures can be achieved and the efficiency of lymph node dissection is considerable ([@b10-etm-0-0-4920],[@b11-etm-0-0-4920]).

Nalbuphine is a type of agonist-antagonist morphine drug with analgesic and sedative effects which was first used clinically in the 1970s ([@b12-etm-0-0-4920]). This study found no significant differences in terms of operation time and intraoperative blood loss between the observation and control groups. However, propofol and remifentanil dosages required in the observation group were significantly lower than in the control group. The effective rate of analgesia was significantly increased and the degree of pain was significantly reduced in the observation group relative to controls as well (p\<0.05). This indicates that the combined effects of nalbuphine, propofol and remifentanil can significantly increase the effect of analgesia, and dosages of propofol and remifentanil can be reduced without affecting the anesthetic effect. We also found that the incidence of adverse reactions such as nausea, vomiting, dizziness and drowsiness was significantly lower in observation group (p\<0.05). Adverse reactions caused by anesthetics are usually mediated by µ receptors. Propofol and remifentanil, which are µ receptor agonist-antagonists, can cause nausea, vomiting and other adverse reactions ([@b13-etm-0-0-4920]). In contrast, nalbuphine can antagonize µ receptors and impart decreased impact on hemodynamics in order to avoid tachycardia. In addition, the inhibitory effect of nalbuphine on respiration is slight and has capping effect ([@b14-etm-0-0-4920]). Nalbuphine is also agonistic to κ receptors, and κ receptors are present in the peripheral and central nervous systems. Agitation of κ receptors can lead to strong and persistent analgesia, which in turn reduces the incidence of adverse effects caused by propofol and remifentanil ([@b15-etm-0-0-4920]).

Lung cancer surgery and anesthesia can both cause stress responses in patients affecting catechol levels, which in turn stimulates the secretion of inflammatory cytokines and causes inflammation ([@b16-etm-0-0-4920]). TNF-α, which is mainly produced by macrophages, NK cells and T lymphocytes, can initiate and trigger inflammation, which in turn leads to tumor cell necrosis and anti-infection immune functions ([@b17-etm-0-0-4920]). IL-6, which is an acute phase response lymphocytic factor, is a member of the IL family, which plays important roles in the immune response ([@b18-etm-0-0-4920]). Another member of interleukin family, IL-10, can inhibit the activity of natural killer cells and depress immune system tumor cell monitoring. Under normal conditions, the expression level of IL-10 is low, but its expression can be significantly increased by inflammation ([@b19-etm-0-0-4920]). In this study, TNF-α, IL-6 and IL-10 levels in the observation group were significantly lower than in the control group at 1, 3, 5 and 7 days post-operation (p\<0.05). Inflammatory cytokine levels peaked on day 3 and started to decline at day 5. Stimulation caused by surgical trauma and anesthetics can lead to a series of stress responses in the body, leading to significantly increased secretion of adrenaline and catechol, which in turn led to increased postoperative levels of TNF-α, IL-6 and IL-10. Nalbuphine can increase the analgesic effect so that traumatic stimulation of the central nerve system can be effectively blocked, thereby reducing the stress response and affecting immune function regulation. Stress response hormone secretion, such as plasma cortisol and catecholamines, can be reduced, and macrophage activation can be inhibited to achieve anti-sympathetic, sedative and antioxidant effects. Therefore, the peripheral and central nervous system sensitization will be reduced and IL-10, TNF-α and IL-6 expression will be downregulated as part of an anti-inflammatory effect ([@b20-etm-0-0-4920]).

In conclusion, the intravenous injection of nalbuphine prior to induction of anesthesia during thoracoscopic lobectomy can effectively relieve perioperative pain and reduce inflammatory responses in patients with lung cancer, thus promoting recovery.

###### 

General patient characteristics.

  Characteristics       Control group (n=46)   Observation group (n=46)   t/χ^2^   P-value
  --------------------- ---------------------- -------------------------- -------- ---------
  Sex (male/female)     29/17                  27/19                      0.046    0.831
  Age (years)           40--70                 40--75                              
  Average age (years)   56.48±7.56             57.23±8.63                 0.443    0.659
  BMI (kg/m^2^)         21.69±3.49             21.83±3.58                 0.190    0.849
  Smoking (n, %)                                                                   
    ≥5 cigarettes       21 (5.65)              18 (39.13)                 0.508    0.776
    \<5 cigarettes      7 (15.22)              9 (19.57)                           
  Non-smoking           18 (39.13)             19 (41.30)                          

###### 

Comparison of surgical conditions and anesthesia effects.

  Groups        Cases   Operation time (min)   Intraoperative blood loss (ml)   Propofol dosage (mg)   Remifentanil dosage (µg)
  ------------- ------- ---------------------- -------------------------------- ---------------------- --------------------------
  Observation   46      124.76±9.15            226.13±9.63                      1084.23±21.53          2204.23±71.53
  Control       46      125.34±9.77            225.87±9.38                      1467.56±22.47          2977.56±72.48
  t-test                1.974                  0.131                            85.544                 51.506
  P-value               0.769                  0.896                            \<0.001                \<0.001

###### 

Comparison of analgesic effects (n, %).

  Groups        Cases   Level I      Level II     Level III    Level IV   Effective rate of analgesia
  ------------- ------- ------------ ------------ ------------ ---------- -----------------------------
  Observation   46      36 (78.26)   7 (15.22)    3 (6.52)     0 (0.00)   43 (93.47)
  Control       46      18 (39.13)   14 (30.43)   11 (23.91)   3 (6.52)   32 (69.56)
  χ^2^                                                                    15.905
  P-value                                                                 0.001

###### 

Comparison of adverse effects caused by anesthetics (n, %).

  Groups        Cases   Nausea      Vomiting   Dizziness   Drowsiness   All adverse effects
  ------------- ------- ----------- ---------- ----------- ------------ ---------------------
  Observation   46      3 (6.52)    1 (2.17)   1 (2.17)    1 (2.17)     6 (13.04)
  Control       46      6 (13.04)   4 (8.70)   5 (10.87)   5 (10.86)    20 (43.48)
  χ^2^                                                                  9.061
  P-value                                                               0.003

###### 

Comparison of TNF-α levels at different time-points (ng/1).

  Groups        Cases   Day 1        Day 3         Day 5        Day 7
  ------------- ------- ------------ ------------- ------------ ------------
  Observation   46      64.19±5.43   98.73±6.14    44.23±5.28   28.78±4.16
  Control       46      73.34±5.74   112.25±6.65   61.75±5.19   39.56±4.43
  t-test                7.854        10.131        16.050       12.031
  P-value               \<0.001      \<0.001       \<0.001      \<0.001

TNF-α, tumor necrosis factor-α.

###### 

Comparison of IL-6 levels at different time-points (ng/1).

  Groups        Cases   Day 1         Day 3         Day 5         Day 7
  ------------- ------- ------------- ------------- ------------- ------------
  Observation   46      126.49±6.68   153.03±8.16   98.53±6.78    52.65±5.26
  Control       46      153.36±6.77   176.54±8.74   129.62±6.87   76.54±5.63
  t-test                19.162        13.355        21.864        21.030
  P-value               \<0.001       \<0.001       \<0.001       \<0.001

IL-6, interleukin-6.

###### 

Comparison of IL-10 levels at different time-points (ng/1).

  Groups        Cases   Day 1         Day 3         Day 5         Day 7
  ------------- ------- ------------- ------------- ------------- ------------
  Observation   46      157.68±7.43   182.34±9.13   124.39±8.28   65.72±5.63
  Control       46      198.18±7.92   213.76±9.68   157.65±8.57   82.93±6.67
  t-test                25.294        16.015        18.930        13.373
  P-value               \<0.001       \<0.001       \<0.001       \<0.001

IL-10, interleukin-10.
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